ABSTRACT
Objective To investigte the correlation between HLX expression level and AML's clinical variables and different risk stratification.Methods A rcal-time quantitative PCR was used to detect HLX expression in the bone marrow mononuclear cells of 32 de novo AML patients with initial treatment.The relationship between HLX expression level and clinical parameters (FAB classification,hemogram,bone marrow progenitor cells,differentiation and different risk stratification) was investigted.Results The HLX expression of patients with AML was significantly decreased in AML-M3 (P ＜ 0.01),and increased in AML-M5 (P ＜ 0.05).It was negatively correlated with bone marrow progenitor cells (P ＜ 0.01),and was positively correlated with the number of peripheral blood platelet (P ＜0.05).The expression of HLX in AML-M3 was positively correlated with peripheral blood leukocyte levels (P ＜ 0.05),and it was negatively correlated with leukocyte cell level in peripheral blood in AML-M5 (P ＜ 0.05).In AML-Ms groups,the expression levels of HLX of poorly differentiated group were significantly higher than those of the well-differentiated groups (P ＜ 0.05).In AML patients with initial treatment in patient group and non-M3 group,there was no significant difference between the low-risk group and the central risk group (P ＞0.05).Conclution HLX expression levels were elevated in some subtypes,such as AML-M5.and there were differences in different FAB types.HLX gene is associated with the proliferation,differentiation and maturation of leukemia cells.However there was no evidence that HLX is different in different AML risk stratification,which needs further experimental studies.
ABSTRACT
Objective To investigate the characteristics of immunophenotyping and clinical significance of MRD analysis in MM patients. Methods Multi-parameter flow cytometry was applied to analyze the immunophenotyping of malignant plasma cells from 172 MM patients, and normal plasma cells from 16 healthy individuals. MRD was analyzed in 32 MM patients with remission. Meanwhile, the effects of MRD status on the disease relapse and patient disease free survival ( DFS ) time was evaluated by following up patients. Results The immunophenotyping of normal plasma cells were CD38, CD138, CD19 and CD45 positive, while the predominant phenotype of MM cells were CD+38( 100.0% ), CD+138( 100.0% ), CD-19 ( 167/172, 97. 1% ), CD+56( 152/172, 88.4% ) and CD-45( 166/172, 96. 5% ). The characteristic markers for MM cells were CD+38, CD-138, CD-19, CD-45 and CD+56. MRD analysis revealed that, among 32 MM patients with remission, 14 patients were MRD negative and 18 patients were MRD positive. During follow-up of 2 to 16 months, the relapse rate in MRD negative patients was significantly lower ( 4/14, 28.6% ) than that of MRD positive patients ( 13/18, 72. 2% ;χ2 =6. 03, P ＜0. 05 ). Furthermore, the DFS time was significantly longer in MRD negative patients[ 16. 23( 10. 37-21.62 )months ] than that of the MRD positive patients [ 10. 07( 3. 79-16. 20 )months,χ2 =7. 53,P ＜0. 05 ]. Conclusions CD+38, CD+138, CD-19, CD-45 and CD+56 are the characteristic markers of MM cells compared to those of the normal plasma cells. MRD analysis is a valuable prognostic factor for MM patients.
ABSTRACT
Objective To investigate expressions of CDev6 and p-ERK1/2 in AML patients and its clinical significance.Methods Expressions of CD44v6 and p-ERK1/2 on bone marrow blasts in 152 AML patients and 22 normal controls were determined by flow cytometry.Meanwhile,the effects of CD44v6 expression(CD+44v6 and CD-44v6) on relapse rate and survival time were analyzed by following up of 129 AML patients.Results Double positive expressions of CD44v6 and p-ERK1/2 were observed in 4.5%(1/22) of the normal bone marrow blasts while single positive expression of CD44v6 and p-ERK1/2 was observed in 36.2%(55/162) and 64.5%(97/162) of AML patients,respectively.The MFI of p-ERK1/2 expression on blast cells in AML patients was [14(7 -58)],which was higher than that in normal controls [8(6 - 10),U =4.2,P＜0.01].Furthermore,MFI of p-ERK1/2 expression on blast cells in CD+44v6 AML patients was [28(15-61)] ,which was significantly higher than that in CD-44v6 AML patients [18(6- 37),U =6.7,P＜0.01].A strong correlation was obtained between CD44v6 and p-ERK1/2 expression(rs = 0.7,P＜ 0.01).Among 129 patients followed up for 4 to 65 months,the data also revealed that the relapse rate of CD-44v6 AML patients was 32.1%(26/81) ,which was much lower than that in CD44v6 AML patients [81.3%(39/48),x2 = 29.13,P＜ 0.01).And the overall survival in CD44v6 AML patients was(28.5 ± 1.8)months,which was significantly worse than that of CD44v6 AML patients [(51.2±2.0) months,x2 =48.2,P＜ 0.01).Conclusion CD44v6 expression was associated with a poor survival in AML patients,and CD44v6 might promote the expansion of leukemic blast cells by up-regulating p-ERK1/2.
ABSTRACT
Objective To investigate the relationship between PTEN mRNA expression and Akt phospholylation in acute leukemia(AL)and explore its clinical significance in the development of acute leukemia.Methods PTEN mRNA expression and Akt phospholylation level in the leukemia cell line K562, HL-60,Jurkat,21 healthy persons and 68 patients with AL were analyzed with RT-PCR and Flow cytometry, respectively.Results(1)The significantly different PTEN mRNA expression was found between the controls and AL patients.85.70% of the normal controls and 26.47% AL patients show positive respectively (?~2=23.38,P